Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OXU-004
- Development stage
- Discontinued
- Lead developer
- Regeneron Pharmaceuticals
- Administration
- Ophthalmic
01
Overview
OXU-004 is a first-in-class investigational treatment developed for uveal melanoma. It was part of Oxular’s pipeline of ophthalmic therapeutics, which focus on innovative drug delivery technologies for retinal diseases. While detailed information about its mechanism of action or molecular modality has not been publicly disclosed, it was positioned as a novel therapy specifically targeting uveal melanoma, a rare and aggressive cancer of the eye. As of the latest available data, development of OXU-004 has been discontinued[2][3].
- Brand names
- OXU-004OXU004OXU 004
- Other names
- OXU-004OXU004OXU 004
Beyond the preview
Go deeper on OXU-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OXU-004.